Neurons expressing neuropeptide Y receptor 2 (NPY2R) represent a key component of the neuropeptide Y (NPY) signaling system in the brain. NPY2R has distinct pharmacological properties from NPY1R, with different tissue distribution and signaling mechanisms. These receptors are particularly important for regulating feeding behavior, energy homeostasis, and stress responses, making them attractive targets for metabolic and neurological disorder therapies.
NPY2R-expressing neurons are distributed across several brain regions:
- Hypothalamus: Arcuate nucleus and paraventricular nucleus, critical for energy balance
- Hippocampus: Dentate gyrus and CA regions, involved in memory and plasticity
- Brainstem: Nucleus tractus solitarius (NTS), regulating autonomic functions
- Cortex: Layer-specific expression in cerebral cortex
- Amygdala: Modulating emotional responses
- Olfactory bulb: Regulating olfactory processing
NPY2R is a 39-kDa GPCR with distinct properties:
- Couples to Gi/o proteins, inhibiting adenylate cyclase
- Exhibits high affinity for NPY and PYY, but not PP
- Undergoes rapid internalization upon agonist binding
- Heterodimerization with NPY1R modifies pharmacology
- Species differences in receptor pharmacology exist
- Mediates satiety signals from peripheral PYY
- Inhibits NPY/AgRP neurons in the arcuate nucleus
- Reduces food intake and body weight
- Modulates leptin and insulin signaling
¶ Stress and Anxiety
- NPY2R signaling modulates anxiety-like behaviors
- Different role from NPY1R in stress responses
- Interacts with CRH and serotonin systems
- Modulates synaptic transmission
- Regulates neuronal excitability
- Influences hippocampal plasticity
- Controls autonomic outflow
- NPY2R activation can be neuroprotective
- Anti-apoptotic signaling mechanisms
- Modulation of inflammatory responses
- Altered NPY2R expression in AD brains
- Potential role in memory impairment
- Therapeutic target for cognitive enhancement
- NPY2R in basal ganglia circuitry
- Modulates dopaminergic signaling
- Possible role in non-motor symptoms
- NPY2R agonists reduce food intake
- PYY acts through NPY2R to induce satiety
- Target for anti-obesity drug development
- NPY2R involvement in mood disorders
- Polymorphisms associated with depression risk
- Novel antidepressant target
- NPY2R has anti-convulsant properties
- Decreased expression in epileptic tissue
- Gene therapy applications
NPY2R is a validated drug target:
- PYY analogs: PYY3-36, synthetic analogs
- Small molecule agonists: Under development
- Peptide-based therapeutics
- BIIE-0246: Research tool compound
- Selective antagonists: For metabolic disorders
- Obesity: NPY2R agonists for weight management
- Metabolic diseases: P therapies
- YY-basedNeurodegeneration: Neuroprotective strategies
NPY2R as a biomarker:
- Genetic variants: NPY2R polymorphisms affect metabolic traits
- Expression studies: Peripheral NPY2R mRNA
- Functional imaging: Developing PET ligands
- PYY and NPY2R in energy homeostasis (2020)
- NPY2R polymorphisms and metabolic traits (2019)
- Neuropeptide Y receptor pharmacology (2016)
- NPY in stress and anxiety (2018)